Xylocaine viscous 2

Manufactured by AstraZeneca

Visit Supplier

Sourced in Japan, United Kingdom

Xylocaine® Viscous 2% is a local anesthetic solution. It contains lidocaine hydrochloride as the active ingredient.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using xylocaine viscous 2

Colonoscopy Preparation and Sedation Protocol

Cited 3 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Colonic preparation before colonoscopy was performed with 2 L of polyethylene glycol solution. Polyethylene glycol solution or magnesium citrate was added when the stool was not a clear liquid [16 (link)].
Experienced endoscopists performed EGD or colonoscopy. Before EGD, local anesthesia of the pharynx was induced using a viscous solution of 2% lidocaine hydrochloride (Xylocaine^® Viscous 2%; AstraZeneca Inc., OSAKA, Japan) [17 (link)]. For endoscopic sedation, midazolam and/or pethidine were used according to the patient’s response [18 (link)]. The doses of midazolam and/or pethidine were determined by each endoscopist. CO₂ was used as insufflation agent for all patients, except those with chronic respiratory failure [19 (link)]. Flumazenil and/or naloxone were used as antagonists of midazolam and/or pethidine for sedation recovery.
The patients were transferred to the recovery room after the procedure. When Aldrete’s scoring system was 9 out of 10, or more, they were discharged from the recovery room [20 (link)]. Their check out time was recorded after they had finished changing their clothes.

Nishizawa T., Yoshida S., Toyoshima O., Matsuno T., Irokawa M., Arano T., Ebinuma H., Suzuki H., Kanai T, & Koike K. (2021). Risk Factors for Prolonged Hospital Stay after Endoscopy. Clinical Endoscopy, 54(6), 851-856.

+ Open protocol

+ Expand

Endoscopic Gastric Examination: Sedation Approach

Check if the same lab product or an alternative is used in the 5 most similar protocols

EGD was performed by 14 experienced endoscopists. EGD was performed as a screening method during a health evaluation, for follow-up of gastritis and/or gastric tumor, for the examination for abdominal symptoms, to investigate an abnormality of photoﬂuorography, to examine abnormal serum pepsinogen levels, or due to a positive finding of H. pylori antibody. The pharynx of the patients was topically anesthetized with a gargle of lidocaine hydrochloride 2% viscous solution (Xylocaine^® Viscous 2%; AstraZeneca Inc., Cambridge, UK) before the EGD.^{(7 )} The endoscopists were allowed to use their clinical judgement to decide the amount and type of sedative and analgesic medication and the antagonist—midazolam (0–10 mg), pethidine (0–70 mg), flumazenil (0–0.5 mg) and naloxone (0–0.4 mg)—to be used. Following the EGD, the patients were transferred to the recovery room. All adverse events including nausea and vomiting were evaluated by the recovery room nurse. Patients were requested to return 10 to 14 days later for the explanation of their EGD results and were also interviewed regarding any additional adverse events.

Nishizawa T., Suzuki H., Arita M., Kataoka Y., Fukagawa K., Ohki D., Hata K., Uraoka T., Kanai T., Yahagi N, & Toyoshima O. (2018). Pethidine dose and female sex as risk factors for nausea after esophagogastroduodenoscopy. Journal of Clinical Biochemistry and Nutrition, 63(3), 230-232.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!